Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-5214 in moderate to severe facial acne vulgaris
ACTRN12624000746538Phase 2Recruiting
- Sponsor
- Atacama Therapeutics, Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acne vulgaris comparing AT-5214 with Placebo (2 arms). Primary endpoint: Change in investigator global assessment score. Started Nov 2024; status: recruiting.
02
Drugs
dexmecamylamine
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ACTRN12624000746538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000746538.